MCID: CCN002
MIFTS: 48

Cocaine Abuse malady

Categories: Mental diseases

Aliases & Classifications for Cocaine Abuse

Aliases & Descriptions for Cocaine Abuse:

Name: Cocaine Abuse 12 52 14 69
Cocaine-Related Disorders 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:809
ICD10 33 F14.1
ICD9CM 35 305.6 305.60
MeSH 42 D019970
SNOMED-CT 64 78267003
UMLS 69 C0009171

Summaries for Cocaine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cocaine despite negative consequences.

MalaCards based summary : Cocaine Abuse, also known as cocaine-related disorders, is related to cerebral atrophy and personality disorder. An important gene associated with Cocaine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and Circadian rythm related genes. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, uterus and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Cocaine Abuse

Diseases related to Cocaine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
id Related Disease Score Top Affiliating Genes
1 cerebral atrophy 29.7 DBH SNCA
2 personality disorder 29.5 DRD2 SLC6A2 SLC6A3 SLC6A4 SNCA
3 schizophrenia 28.6 DBH DRD2 HTR3A MAOB PRL SLC18A2
4 rhinoscleroma 10.3 DRD2 PRL
5 lung occult small cell carcinoma 10.2 DRD2 PRL
6 pfeiffer rockelein syndrome 10.2 DRD2 PRL
7 classic pulmonary blastoma 10.2 DRD2 SNCA
8 lower gum cancer 10.2 SLC6A3 SNCA
9 euthyroid sick syndrome 10.2 DRD2 SLC6A4
10 intracranial cavernous angioma 10.2 DRD2 SLC6A3 SLC6A4
11 splenic abscess 10.2 DRD2 SLC6A3 SLC6A4
12 18p deletion syndrome 10.2 DRD2 SLC6A3
13 familial spastic paralysis 10.2 DBH SNCA
14 apperceptive agnosia 10.2 DRD2 SLC6A4
15 carotid stenosis 10.2 DRD2 SLC6A3 SLC6A4
16 cholesteatoma 10.2 DRD2 SLC6A3 SLC6A4
17 conjunctival pigmentation 10.2 MAOB SLC6A4
18 hypereosinophilic syndrome 10.2 DRD2 SLC6A3 SLC6A4
19 alopecia 10.1 DRD2 PRL SLC6A4
20 scoliosis 10.1 DBH DRD2 SLC6A3
21 waardenburg's syndrome 10.1 DRD2 SLC6A4
22 autism spectrum disorder 10.1 SLC6A2 SLC6A3 SLC6A4
23 interstitial emphysema 10.1 DBH DRD2 SLC6A4
24 anodontia 10.1 HTR3A SLC6A3 SLC6A4
25 rectosigmoid junction neoplasm 10.1 DRD2 SLC18A2 SLC6A3
26 pulmonary neuroendocrine tumor 10.1 DRD2 PRL
27 littre gland carcinoma 10.1 MAOB SLC6A2 SLC6A3
28 cerebritis 10.1
29 riedel's fibrosing thyroiditis 10.1 MAOB SNCA
30 fechtner syndrome 10.1 HTR3A SLC6A2 SLC6A4
31 renpenning syndrome 10.1 DBH HTR3A SLC6A4
32 alzheimer disease 17 10.1 PRL SLC18A2 SLC6A4
33 mitochondrial dna depletion syndrome 3 10.1 SLC18A2 SLC6A3 SNCA
34 microcephaly 13, primary, autosomal recessive 10.0 DRD2 HTR3A SLC6A4
35 brain glioblastoma multiforme 10.0 DRD2 SLC6A3 SLC6A4
36 ornithosis 10.0 DRD2 HTR3A PRL SLC6A4
37 pythiosis 10.0 DBH MAOB SNCA
38 hepatitis b reinfection following liver transplantation 10.0 HTR3A MAOB SLC6A4
39 pyromania 10.0 DRD2 MAOB SLC6A3 SLC6A4
40 strongyloidiasis 10.0 DRD2 MAOB SLC6A3 SLC6A4
41 cecal benign neoplasm 10.0 DRD2 MAOB SLC6A3 SLC6A4
42 substance-induced psychosis 10.0 MAOB SLC6A3 SNCA
43 kidney pelvis papillary carcinoma 10.0 SLC6A2 SLC6A4
44 postencephalitic parkinson disease 10.0 DRD2 HTR3A SLC6A2 SLC6A4
45 multiple system atrophy 10.0 MAOB SLC18A2 SNCA
46 aortic valve disease 2 10.0 DBH DRD2 HTR3A SLC6A3
47 myocardial infarction 10.0
48 ischemia 10.0
49 vasculitis 10.0
50 cardiomyopathy 10.0

Comorbidity relations with Cocaine Abuse via Phenotypic Disease Network (PDN):


Alcohol Abuse

Graphical network of the top 20 diseases related to Cocaine Abuse:



Diseases related to Cocaine Abuse

Symptoms & Phenotypes for Cocaine Abuse

MGI Mouse Phenotypes related to Cocaine Abuse:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 MAOB PRL SLC17A8 SLC18A2 SLC6A2 SLC6A3
2 homeostasis/metabolism MP:0005376 10 CARTPT DBH DRD2 HTR3A MAOB PRL
3 endocrine/exocrine gland MP:0005379 9.97 CARTPT DBH DRD2 HTR3A PRL SLC6A3
4 growth/size/body region MP:0005378 9.97 DBH DRD2 HTR3A SLC18A2 SLC6A2 SLC6A3
5 integument MP:0010771 9.81 DBH DRD2 HTR3A PRL SLC17A8 SLC6A2
6 nervous system MP:0003631 9.7 DBH DRD2 HTR3A MAOB PRL SLC17A8
7 taste/olfaction MP:0005394 8.92 DRD2 SLC18A2 SLC6A3 SNCA

Drugs & Therapeutics for Cocaine Abuse

Drugs for Cocaine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 363)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
4
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 561-27-3 5462328
5
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
6
Amphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 300-62-9 5826 3007
7
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
8
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
9
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
10
Methamphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 537-46-2 10836
11
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1 76-99-3 4095
12
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 16590-41-3 5360515
13
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
14
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68693-11-8 4236
15
Biperiden Approved Phase 4,Phase 2,Phase 3 514-65-8 2381
16
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112111-43-0
17
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
18
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
19
Nicotine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 54-11-5 942 89594
20
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 465-65-6 5284596
21
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 34841-39-9, 34911-55-2 444
22
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 113-45-1 4158
23
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-56-6 439302 53477758
24
Amantadine Approved Phase 4,Phase 2,Phase 1 768-94-5 2130
25
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
26
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
27
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
28
Caffeine Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 58-08-2 2519
29
Choline Approved, Nutraceutical Phase 4,Phase 3 62-49-7 305
30 Quetiapine Fumarate Phase 4,Phase 2,Phase 1 111974-72-2
31 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
32 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1
33
Serotonin Phase 4,Phase 2,Phase 3,Phase 1 50-67-9 5202
34 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
35 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
36 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1
37 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Serotonin Antagonists Phase 4,Phase 2,Phase 1
41 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
42 Gastrointestinal Agents Phase 4,Phase 2
43 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
47 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 1
48 Dermatologic Agents Phase 4,Phase 2
49 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
50 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 522)
id Name Status NCT ID Phase
1 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4
2 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4
3 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
4 Cognitive Correlates of Substance Abuse, Part 2 - 16 Unknown status NCT00000351 Phase 4
5 Relapse Patterns in Female Cocaine Users - 4 Completed NCT00000287 Phase 4
6 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
7 Brain Imaging: Cocaine Effects & Medication Development - 5 Completed NCT00000270 Phase 4
8 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4
9 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4
10 Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11 Completed NCT00015301 Phase 4
11 Modeling Impaired Judgement in Cocaine Abusers - 6 Completed NCT00015236 Phase 4
12 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4
13 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4
14 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency Completed NCT00280293 Phase 4
15 An Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4
16 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
17 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4
18 The Maternal Lifestyle Study (MLS) Completed NCT00059540 Phase 4
19 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4
20 Brain Changes in Stimulant Dependent Subjects - 8 Completed NCT00000343 Phase 4
21 Effects of Modafinil in Methamphetamine Dependence Completed NCT00751023 Phase 4
22 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
23 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
24 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4
25 Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Recruiting NCT03018236 Phase 4
26 Advancing Tobacco Use Treatment for African American Smokers Recruiting NCT02360631 Phase 4
27 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4
28 A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts Withdrawn NCT02134002 Phase 4
29 Effectiveness of Topiramate in Treating Cocaine Dependent Individuals - 1 Unknown status NCT00249691 Phase 3
30 Combining Behavioral Treatment With Agonist Maintenance - 1 Unknown status NCT00000311 Phase 3
31 Novel Pharmacotherapy for Dual Dependence Unknown status NCT00448825 Phase 3
32 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
33 Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients Completed NCT00495092 Phase 2, Phase 3
34 Selegiline Transdermal System for the Treatment of Cocaine Dependence - 1 Completed NCT00032929 Phase 3
35 Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10 Completed NCT00000293 Phase 3
36 Dose Response Trial of Pergolide for Cocaine Dependence - 1 Completed NCT00000248 Phase 3
37 Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1 Completed NCT00000216 Phase 3
38 Cocaine Use Reduction With Buprenorphine Completed NCT01402492 Phase 2, Phase 3
39 Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine Dependence Completed NCT01468012 Phase 2, Phase 3
40 Cocaine/Crack and Reduction of Compulsion With Biperiden Completed NCT01251393 Phase 3
41 Clinical Neurobiology of Serotonin and Addiction Completed NCT00732901 Phase 2, Phase 3
42 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study Completed NCT00632099 Phase 2, Phase 3
43 Adaptive Treatment for Alcohol and Cocaine Dependence Completed NCT01032135 Phase 2, Phase 3
44 Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence Completed NCT00223236 Phase 3
45 Smoking-Cessation and Stimulant Treatment (S-CAST) Completed NCT01077024 Phase 3
46 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1 Completed NCT00218660 Phase 3
47 Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence Completed NCT00167232 Phase 3
48 Vigabatrin for the Treatment of Cocaine Dependency Completed NCT01281202 Phase 2, Phase 3
49 Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction Completed NCT00701532 Phase 3
50 Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1 Completed NCT00061087 Phase 2, Phase 3

Search NIH Clinical Center for Cocaine Abuse

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: cocaine-related disorders

Genetic Tests for Cocaine Abuse

Anatomical Context for Cocaine Abuse

MalaCards organs/tissues related to Cocaine Abuse:

39
Brain, Uterus, Testes, Placenta, Lung, Pituitary, Amygdala

Publications for Cocaine Abuse

Articles related to Cocaine Abuse:

(show top 50) (show all 575)
id Title Authors Year
1
Impact on Cortical Function of Cocaine Abuse Co-Occurring with HIV. ( 27909321 )
2017
2
Cocaine abuse determination by ion mobility spectrometry using molecular imprinting. ( 28012589 )
2017
3
Resting state brain connectivity patterns before eventual relapse into cocaine abuse. ( 28057531 )
2017
4
Adolescent d-amphetamine treatment in a rodent model of attention deficit/hyperactivity disorder: impact on cocaine abuse vulnerability in adulthood. ( 27600990 )
2016
5
Plant expression of cocaine hydrolase-Fc fusion protein for treatment of cocaine abuse. ( 27756365 )
2016
6
Cocaine and crack cocaine abuse by pregnant or lactating mothers and analysis of its biomarkers in meconium and breast milk by LC-MS-A review. ( 26827634 )
2016
7
Increased MFG-E8 expression and its implications in the vascular pathophysiology of cocaine abuse. ( 27182119 )
2016
8
Relationship between coronary artery ectasia, cocaine abuse and acute coronary syndromes. ( 27231522 )
2016
9
Cocaine abuse that presents with acute scrotal pain and mimics testicular torsion. ( 27583357 )
2016
10
Cocaine abuse and effects in the serum levels of cytokines IL-6 and IL-10. ( 26679059 )
2016
11
Cocaine Abuse: An Unusual Association. ( 27805341 )
2016
12
A case of iloperidone overdose in a 27-year-old man with cocaine abuse. ( 27570623 )
2016
13
Plasma Selenium Levels in Chronic Cocaine Abuse. ( 27349018 )
2016
14
Multiple Pyoderma Gangrenosum Ulcers Associated with Cocaine Abuse. ( 28003907 )
2016
15
Extensive Necrotic Purpura in Levamisole-Adulterated Cocaine Abuse - A Case Report. ( 27500987 )
2016
16
The Ventral Pallidum: Proposed Integrator of Positive and Negative Factors in Cocaine Abuse. ( 27710789 )
2016
17
Multifocal and refractory pyoderma gangrenosum: Possible role of cocaine abuse. ( 27250583 )
2016
18
Behaviour of hygrine and cuscohygrine in illicit cocaine production establishes their use as markers for chewing coca leaves in contrast with cocaine abuse. ( 27004438 )
2016
19
Atraumatic splenic rupture and ileal volvulus following cocaine abuse. ( 26324218 )
2015
20
Membranous glomerulonephritis and cellular crescents induced by levamisole-adulterated cocaine abuse: a case report. ( 26605317 )
2015
21
The absence of VGLUT3 predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. ( 26239290 )
2015
22
Investigating the potential influence of cause of death and cocaine levels on the differential expression of genes associated with cocaine abuse. ( 25658879 )
2015
23
Neuropsychological impairments associated with the relation between cocaine abuse and violence: neurological facilitation mechanisms. ( 25879478 )
2015
24
The most dangerous complication of intranasal cocaine abuse in a young man: cardiac arrest. ( 26778640 )
2015
25
Identification of long noncoding RNAs dysregulated in the midbrain of human cocaine abusers. ( 26222413 )
2015
26
Cocaine abuse, retiform purpura and antiphospholipid syndrome. ( 26070938 )
2015
27
Impact of cocaine abuse on HIV pathogenesis. ( 26539167 )
2015
28
Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: A comprehensive narrative overview of English-language studies. ( 25662894 )
2015
29
Prosthetic Management for a Palatal Perforation from Cocaine Abuse. ( 25557361 )
2015
30
Assessing cocaine abuse using LC-MS/MS measurements in biological specimens. ( 26168256 )
2015
31
Cocaine Abuse in Later Life: A Case Series and Review of the Literature. ( 26445694 )
2015
32
Platelet Activation in Human Immunodeficiency Virus Type-1 Patients Is Not Altered with Cocaine Abuse. ( 26076359 )
2015
33
Multiple gastrointestinal complications of crack cocaine abuse. ( 24839446 )
2014
34
Application of hygrine and cuscohygrine as possible markers to distinguish coca chewing from cocaine abuse on WDT and forensic cases. ( 24656326 )
2014
35
Association between smoking, crack cocaine abuse and the discontinuation of combination antiretroviral therapy in Recife, Pernambuco, Brazil. ( 24626414 )
2014
36
Pyoderma gangrenosum: a possible cutaneous complication of levamisole-tainted cocaine abuse. ( 24898775 )
2014
37
Salvinorin A analogs and other I_-opioid receptor compounds as treatments for cocaine abuse. ( 24484985 )
2014
38
Cocaine abuse during pregnancy. ( 25184982 )
2014
39
Acute morphine and cocaine related death after trimethoprim-adultered cocaine abuse. ( 25361939 )
2014
40
Environmental modulation of drug taking: Nonhuman primate models of cocaine abuse and PET neuroimaging. ( 23748095 )
2014
41
Facial Cutaneous Necrosis Associated With Suspected Levamisole Toxicity From Tainted Cocaine Abuse. ( 25015925 )
2014
42
Cocaine abuse in humans is not associated with increased microglial activation: an 18-kDa translocator protein positron emission tomography imaging study with [11C]PBR28. ( 25057196 )
2014
43
A molecular profile of cocaine abuse includes the differential expression of genes that regulate transcription, chromatin, and dopamine cell phenotype. ( 24642598 )
2014
44
Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects. ( 22026501 )
2014
45
Cocaine abuse and confidentiality: a case of retiform purpura in an adolescent patient. ( 24831315 )
2014
46
Acute coronary syndrome after levamisole-adultered cocaine abuse. ( 24365689 )
2014
47
Trace amines and cocaine abuse. ( 24849494 )
2014
48
ST-segment elevation in patients with cocaine abuse and chest pain. ( 24940570 )
2014
49
Cardiac Fas-dependent and mitochondria-dependent apoptosis after chronic cocaine abuse. ( 24722570 )
2014
50
Gastrointestinal complications and esophageal stenosis after crack cocaine abuse. ( 24008469 )
2013

Variations for Cocaine Abuse

Expression for Cocaine Abuse

Search GEO for disease gene expression data for Cocaine Abuse.

Pathways for Cocaine Abuse

GO Terms for Cocaine Abuse

Cellular components related to Cocaine Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.56 HTR3A SLC17A8 SLC6A3 SNCA
2 membrane raft GO:0045121 9.5 SLC6A2 SLC6A3 SLC6A4
3 neuron projection GO:0043005 9.46 SLC17A8 SLC6A2 SLC6A3 SLC6A4
4 axon GO:0030424 9.26 DRD2 HTR3A SLC6A3 SNCA
5 axon terminus GO:0043679 8.8 DRD2 SLC17A8 SNCA

Biological processes related to Cocaine Abuse according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.93 SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4
2 chemical synaptic transmission GO:0007268 9.83 CARTPT DBH SLC18A2 SLC6A2 SNCA
3 response to lipopolysaccharide GO:0032496 9.82 MAOB PRL SNCA
4 response to drug GO:0042493 9.8 DRD2 MAOB PRL SLC6A2 SLC6A3 SLC6A4
5 response to toxic substance GO:0009636 9.78 DRD2 MAOB SLC18A2 SLC6A4
6 locomotory behavior GO:0007626 9.76 DBH DRD2 SLC18A2 SLC6A3
7 response to ethanol GO:0045471 9.72 DRD2 HTR3A MAOB PRL SLC6A3
8 response to amphetamine GO:0001975 9.67 DBH DRD2 SLC18A2
9 response to cocaine GO:0042220 9.67 DRD2 HTR3A SLC6A3 SNCA
10 positive regulation of multicellular organism growth GO:0040018 9.65 DRD2 SLC6A3
11 associative learning GO:0008306 9.64 DBH DRD2
12 regulation of dopamine secretion GO:0014059 9.63 DRD2 SNCA
13 behavioral response to cocaine GO:0048148 9.63 DRD2 SNCA
14 response to pain GO:0048265 9.62 DBH SLC6A2
15 response to iron ion GO:0010039 9.62 DRD2 SLC6A3
16 synaptic transmission, dopaminergic GO:0001963 9.61 DRD2 SNCA
17 regulation of long-term neuronal synaptic plasticity GO:0048169 9.61 DRD2 SNCA
18 behavioral response to ethanol GO:0048149 9.6 DBH DRD2
19 neurotransmitter biosynthetic process GO:0042136 9.59 SLC6A3 SLC6A4
20 dopamine metabolic process GO:0042417 9.58 DRD2 SNCA
21 ammonium transmembrane transport GO:0072488 9.58 SLC6A3 SLC6A4
22 dopamine catabolic process GO:0042420 9.58 DBH MAOB SLC6A3
23 prepulse inhibition GO:0060134 9.57 DRD2 SLC6A3
24 dopamine biosynthetic process GO:0042416 9.56 SLC6A3 SNCA
25 adenohypophysis development GO:0021984 9.55 DRD2 SLC6A3
26 neurotransmitter transport GO:0006836 9.55 SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4
27 dopamine transport GO:0015872 9.52 SLC18A2 SLC6A3
28 serotonin transport GO:0006837 9.51 SLC18A2 SLC6A4
29 monoamine transport GO:0015844 9.26 SLC18A2 SLC6A2 SLC6A3 SLC6A4
30 dopamine uptake involved in synaptic transmission GO:0051583 8.92 SLC6A2 SLC6A3 SLC6A4 SNCA
31 transport GO:0006810 10.13 HTR3A SLC17A8 SLC18A2 SLC6A2 SLC6A3 SLC6A4

Molecular functions related to Cocaine Abuse according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 symporter activity GO:0015293 9.46 SLC17A8 SLC6A2 SLC6A3 SLC6A4
2 beta-tubulin binding GO:0048487 9.43 SLC6A2 SNCA
3 alpha-tubulin binding GO:0043014 9.4 SLC6A2 SNCA
4 neurotransmitter:sodium symporter activity GO:0005328 9.37 SLC6A3 SLC6A4
5 dopamine binding GO:0035240 9.32 DRD2 SLC6A3
6 serotonin transmembrane transporter activity GO:0015222 9.26 SLC18A2 SLC6A4
7 dopamine:sodium symporter activity GO:0005330 9.13 SLC6A2 SLC6A3 SLC6A4
8 monoamine transmembrane transporter activity GO:0008504 8.92 SLC18A2 SLC6A2 SLC6A3 SLC6A4

Sources for Cocaine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....